Feb 20, 2026High Glycation Burden: Carnosine and Metformin in Clinical ContextLowering glycation burden is mainly a glucose-control and dietary strategy. Carnosine and metformin may support risk reduction in selected contexts, with different evidence depth and safety constraints.
Feb 5, 2026Metformin for Longevity: TAME Trial, Off-Label Use in Non-Diabetics, Safety, and ContraindicationsMetformin activates AMPK and has extensive epidemiological longevity data from diabetic populations. The TAME trial will provide the first RCT data for longevity in non-diabetics. Off-label use has meaningful risks including vitamin B12 depletion, GI effects, and contraindications.